Results 131 to 140 of about 12,080 (218)

Dual Targeting Ligands-Histamine H₃ Receptor Ligands with Monoamine Oxidase B Inhibitory Activity-In Vitro and In Vivo Evaluation. [PDF]

Pharmaceutics, 2022
Łażewska D, Siwek A, Olejarz-Maciej A, Doroz-Płonka A, Wiktorowska-Owczarek A, Jóźwiak-Bębenista M, Reiner-Link D, Frank A, Sromek-Trzaskowska W, Honkisz-Orzechowska E, Królicka E, Stark H, Wieczorek M, Wagner W, Kieć-Kononowicz K, Stasiak A.   +15 more
europepmc   +1 more source

Benzophenone Derivatives with Histamine H₃ Receptor Affinity and Cholinesterase Inhibitory Potency as Multitarget-Directed Ligands for Possible Therapy of Alzheimer's Disease. [PDF]

Molecules, 2022
Godyń J, Zaręba P, Stary D, Kaleta M, Kuder KJ, Latacz G, Mogilski S, Reiner-Link D, Frank A, Doroz-Płonka A, Olejarz-Maciej A, Sudoł-Tałaj S, Nolte T, Handzlik J, Stark H, Więckowska A, Malawska B, Kieć-Kononowicz K, Łażewska D, Bajda M.   +19 more
europepmc   +1 more source

Correction: Histamine H3 Receptor as a target for alcohol use disorder: challenging the predictability of animal models for clinical translation in drug development. [PDF]

Transl Psychiatry
Le Foll B, Naassila M, Jeanblanc J, Hendershot CS, Chavarria J, Calmels T, Krief S, Berrebi-Bertrand I, Uguen M, Perrin D, Ligneau X, Boileau I, Rusjan PM, Di Ciano P, Sabioni P, Capet M, Robert P, Finance O, Lecomte JM, Schwartz JC.   +19 more
europepmc   +1 more source

Biphenylalkoxyamine Derivatives-Histamine H₃ Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. [PDF]

Molecules, 2021
Łażewska D, Zaręba P, Godyń J, Doroz-Płonka A, Frank A, Reiner-Link D, Bajda M, Stary D, Mogilski S, Olejarz-Maciej A, Kaleta M, Stark H, Malawska B, Kieć-Kononowicz K.   +13 more
europepmc   +1 more source

Histamine H3 Receptor as a target for alcohol use disorder: challenging the predictability of animal models for clinical translation in drug development. [PDF]

Transl Psychiatry
Le Foll B, Naassila M, Jeanblanc J, Hendershot CS, Chavarria J, Calmels T, Krief S, Berrebi-Bertrand I, Uguen M, Perrin D, Ligneau X, Boileau I, Rusjan PM, Di Ciano P, Sabioni P, Capet M, Robert P, Finance O, Lecomte JM, Schwartz JC.   +19 more
europepmc   +1 more source

Histamine H3 Receptor Antagonist, Thioperamide, Improves Behavioral and Neuropathological Changes Associated with Subclinical Hypersensitivity to a Cow's Milk Allergen. [PDF]

J Neuroimmune Pharmacol
Germundson-Hermanson D, Klug MG, Nagamoto-Combs K.   +2 more
europepmc   +1 more source

The dual G9a inhibitor and histamine H3 receptor antagonist A-366 improves repetitive and social behaviors and attenuates neuroinflammation in BTBR T + tf/J mice. [PDF]

Sci Rep
Hajar M, Jayaprakash P, Stark H, Sadek B.   +3 more
europepmc   +1 more source

CNS-Sparing Histamine H₃ Receptor Antagonist as a Candidate to Prevent the Diabetes-Associated Gastrointestinal Symptoms. [PDF]

Biomolecules, 2022
Rosa AC, Nardini P, Sgambellone S, Gurrieri M, Spampinato SF, Dell'Accio A, Chazot PL, Obara I, Liu WL, Pini A.   +9 more
europepmc   +1 more source

Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis. [PDF]

Neuropsychopharmacol Rep
Nishii Y, Sakuma K, Hamanaka S, Iwata N, Kishi T.   +4 more
europepmc   +1 more source

Discovery of Potential, Dual-Active Histamine H₃ Receptor Ligands with Combined Antioxidant Properties. [PDF]

Molecules, 2021
Kuder KJ, Kotańska M, Szczepańska K, Mika K, Reiner-Link D, Stark H, Kieć-Kononowicz K.   +6 more
europepmc   +1 more source